PDF(793 KB)
Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro
Yongjing YANG,Tianyang KE,Shixin LIU,Xue WANG,Dequan XU,Tingting LIU,Ling ZHAO
PDF(793 KB)
PDF(793 KB)
Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro
)Objective To discuss the synergistic inhibitory effect of apatinib mesylate （apatinib） combined with radiotherapy （RT） on the hepatocellular carcinoma （HepG2） cells in vitro， and to clarify its related antitumor mechanism. Methods The HepG2 cells were cultured in vitro and treated with different concentrations of apatinib and/or varying doses of X-rays. MTT method was used to detect the survival rates of the cells in various groups； the inhibitory rates of cell proliferation and the 20% inhibitory concentration （IC20） of apatinib were calculated； the X-ray irradiation dose for subsequent experiments was detected. The HepG2 cells were divided into apatinib group， RT group， and apatinib+RT group （combined group）. Flow cytometry was used to detect the apoptotic rates of the cells in various groups； wound healing assay was used to detect the migration rates of the cells in various groups； ELISA method was used to detect the levels of vascular endothelial growth factor （VEGF） in the cell culture supernatant in various groups. Results The MTT results showed that the IC20 of apatinib was 1.32 μmol·L-1， and this concentration was used for subsequent experiments， and the X-ray irradiation dose for the follow-up experiments was 2 Gy. Compared with control group， the apoptotic rates of the cells in apatinib group and RT group had no significant differences （P>0.05）， while the apoptotic rate of the cells in combined group was increased （P<0.05）. Compared with control group， the migration rates of the cells in apatinib group， RT group， and combined group were decreased （P<0.05）； compared with apatinib group and RT group， the migration rate of the cells in combined group was decreased （P<0.05）. Compared with control group， the levels of VEGF in the cell culture supernatant in apatinib group and combined group were decreased （P<0.05）； compared with apatinib and RT group， the level of VEGF in the cell culture supernatant in combined group was decreased （P<0.05）. Conclusion Apatinib combined with radiotherapy significantly inhibits the proliferation and migration of the HepG2 cells in vitro and induces the apoptosis； its effect may be related to the inhibition of VEGF secretion by cells.
Hepatocellular carcinoma / Apatinib mesylate / Radiotherapy / Cell proliferation / Apoptosis / Cell migration / Vascular endothelial growth factor
R735.7
| 1 | CHEN W， ZHENG R， BAADE P D， et al. Cancer statistics in China， 2015［J］. Ca A Cancer J Clin， 2016， 66（2）：115-132． |
| 2 | WANG H， ZHU X， ZHAO Y， et al. Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma［J］. BMC Cancer， 2022， 22（1）：771. |
| 3 | QIU H， KE S， CAI G， et al. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma［J］. Cancer Med， 2023，12（1）：213-222. |
| 4 | LIU X， LUO J， ZHANG L， et al. SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization［J］. Clin Res Hepatol Gastroenterol， 2022，46（6）：101897. |
| 5 | DVORAK H F. Tumor stroma， tumor blood vessels， and antiangiogenesis therapy［J］. Cancer J， 2015，21（4）：237-243. |
| 6 | RIM C H， SEONG J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines［J］. Radiat Oncol J， 2016 Sep； 34（3）：160-167. |
| 7 | JIANG S， ZHOU Y， ZOU L， et al. Low- dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer［J］. Cancer Med， 2023， 12（4）： 4434-4445. |
| 8 | 冯久桓， 秦叔逵， 王 琳. 甲磺酸阿帕替尼的研究现状与进展［J］. 临床肿瘤学杂志， 2017， 22（4）： 345-356. |
| 9 | 孙 菲， 孙志强， 汪建林， 等. 阿帕替尼对食管癌 Kyse150 细胞放射敏感性影响的实验研究［J］．中华放射医学与防护杂志，2017， 37（11）： 805-809． |
| 10 | 刘 伟，张建文. 阿帕替尼联合放疗对 HeLa 细胞周期和凋亡影响的体外研究［J］．安徽医科大学学报，2018，53 （1）： 55-58. |
| 11 | LIANG L J， HU C X， WEN Y X， et al. Apatinib combined with local irradiation leads to systemic tumor control via reversal of immunosuppressive tumor microenvironment in lung cancer［J］. Cancer Res Treat， 2020，52（2）：406-418. |
| 12 | QIN S， LI Q， GU S， et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma （AHELP）： a multicentre， double-blind， randomised， placebo-controlled， phase 3 trial［J］. Lancet Gastroenterol Hepatol， 2021，6（7）：559-568. |
| 13 | 张延藏， 王满周， 韩新巍， 等. 载药栓塞微球经肝动脉化疗栓塞术联合阿帕替尼治疗不可切除肝癌后二线追加卡瑞利珠单抗的安全性和有效性分析［J］. 临床肝胆病杂志， 2023， 39（4）： 834-842. |
| 14 | HU Y， QIN T， LI S， et al. Efficacy and safety of SBRT combined with Camrelizumab and Apatinib in HCC patients with PVTT： Study protocol of a randomized controlled trial［J］. Front Oncol， 2020，26（10）：1589. |
| 15 | 姜增凯， 叶晓歌， 陈琴华. 阿帕替尼对肝癌细胞增殖和迁移能力的影响研究［J］. 中国临床药理学杂志， 2016， 32（15）：1422-1424． |
| 16 | QI X， YANG M， MA L， et al. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response［J］. J Immunother Cancer， 2020， 8（2）：e001038. |
| 17 | SONG J， GUAN Z， SONG C， et al. Apatinib suppresses the migration， invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways［J］. Mol Med Rep， 2021，23（6）：429. |
| 18 | 殷 亮， 王 荩， 黄凤昌， 等. 甲磺酸阿帕替尼对结肠癌 HCT-116 细胞增殖的抑制作用及其机制［J］. 南方医科大学学报，2017， 3： 367-372. |
| 19 | HSU H W， GRIDLEY D S， KIM P D， et al. Linifanib （ABT-869） enhance radiosensitivity of head and neck squamous cell carcinoma cells［J］. Oral Oncol， 2013， 49（6）： 591-597. |
| 20 | MEIJER T W， KAANDERS J H， SPAN P N， et al. Targeting hypoxia， HIF-1， and tumor glucose metabolism to improve radiotherapy effcacy［J］. Clin Cancer Res， 2012， 18（20）： 5585-5594. |
| 21 | 王一， 李锦毅. 索拉非尼与阿帕替尼对人肝癌 SMMC-7721 细胞的抑制作用比较［J］. 中华灾害救援医学， 2017， 5 （12）： 681-684. |
| 22 | LIN D， WU J. Hypoxia inducible factor in hepatocellular carcinoma： A therapeutic target［J］. World J Gastroenterol， 2015，21（42）： 12171-12178. |
| 23 | NG E W， SHIMA D T， CALIAS P， et al. Pegaptanib， a targeted anti-VEGF aptamer for ocular vascular disease［J］. Nat Rev Drug Discov， 2006， 5（2）： 123-132. |
| 24 | BROWN DM， REGILLO CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration： applying clinical trial results to the treatment of everyday patients［J］. Am J Ophthalmol， 2007， 144（4）：627-37. |
| 25 | CHEN Y， CHEN X， DING X， et al. Afatinib， an EGFR inhibitor， decreases EMT and tumorigenesis of Huh-7 cells by regulating the ERK-VEGF/MMP9 signaling pathway［J］. Mol Med Rep， 2019， 20（4）：3317-3325. |
| 26 | ZHANG H H， ZHANG Y， CHENG Y N， et al. Metformin incombination with curcumin inhibits the growth， metastasis， and angiogenesis of hepatocellular carcinoma in vitro and in vivo ［J］. Mol Carcinog， 2018， 57（1）：44-56. |
| 27 | LIAO J， JIN H， LI S， et al. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma［J］. J Exp Clin Cancer Res， 2019，38（1）：454. |
| 28 | 朱丽珍， 许晓磊， 阿卜杜萨拉木·艾尼， 等. 肝细胞癌免疫治疗研究进展［J］. 临床肝胆病杂志， 2023， 39（5）：1197-1203. |
/
| 〈 |
|
〉 |
AI Summary
